{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:11Z","timestamp":1761518891812},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1007\/bf02967623","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T06:49:13Z","timestamp":1223362153000},"page":"33-37","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy"],"prefix":"10.1007","volume":"10","author":[{"given":"Norio","family":"Kohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kokufu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02967623_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","volume":"3","author":"HL Arams","year":"1950","unstructured":"Arams HL, Spiro R, Goldstein M: Metastases in carcinoma: analysis of 1000 autopsied cases.Cancer 3: 74\u201376, 1950.","journal-title":"Cancer"},{"key":"BF02967623_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD1: The clinical course of bone metastases from breast cancer.Br J Cancer 55: 61\u201366, 1987.","journal-title":"Br J Cancer"},{"issue":"(suppl 8)","key":"BF02967623_CR3","first-page":"1588","volume":"80","author":"RE Coleman","year":"1998","unstructured":"Coleman RE: Skeletal complications of malignancy.Cancer 80 (suppl 8): 1588\u20131594, 1998.","journal-title":"Cancer"},{"key":"BF02967623_CR4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199808063390609","volume":"339","author":"GR Mundy","year":"1998","unstructured":"Mundy GR and Yoneda T: Bisphosphonates as anticancer drugs.N Engl J Med 339: 398\u2013400, 1998.","journal-title":"N Engl J Med"},{"key":"BF02967623_CR5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1172\/JCI113358","volume":"81","author":"AF Stewart","year":"1988","unstructured":"Stewart AF, Margin M, Wu T,et al: Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.J Clin Inves 81: 932\u2013938, 1988.","journal-title":"J Clin Inves"},{"key":"BF02967623_CR6","first-page":"3059","volume":"51","author":"GJ Powell","year":"1991","unstructured":"Powell GJ, Southby J, Danks JA,et al: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.Cancer Res 51: 3059\u20133061, 1991.","journal-title":"Cancer Res"},{"key":"BF02967623_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02967374","volume":"1","author":"N Kohno","year":"1994","unstructured":"Kohno N, Kitazawa S, Sakoda Y,et al: Parathyroid hormone-related protein in breast cancer tissues: relationship between primary and metastatic sites.Breast Cancer 1: 43\u201349, 1994.","journal-title":"Breast Cancer"},{"key":"BF02967623_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/ar127","volume":"2","author":"S Roux","year":"2000","unstructured":"Roux S, Orcel P: Bone loss. Factors that regulate ostoclast differentiation: an up date.Arthritis Res 2: 451\u2013456, 2000.","journal-title":"Arthritis Res"},{"key":"BF02967623_CR9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","volume":"98","author":"TA Guise","year":"1996","unstructured":"Guise TA, Yin JJ, Taylor SD,et al: Evidence for causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.J Clin Invest 98: 1544\u20131549, 1996.","journal-title":"J Clin Invest"},{"key":"BF02967623_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2","volume":"72","author":"B Krempien","year":"1993","unstructured":"Krempien B, Manegold C: Prophylactic treatment of skeletal metastases. tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphopnate CL2MBP.Cancer 72: 91\u201398, 1993.","journal-title":"Cancer"},{"key":"BF02967623_CR11","unstructured":"Krempien B: Experimental findings on the osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: a pleading for an early and preventive administration, In: Orr FW and Singh G eds, Bone Metastases \u2014 Mechanisms and Pathophysiology, Landess, Gergetown, pp221\u2013244."},{"key":"BF02967623_CR12","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A, Boyce BF, Wright KR,et al: Bisphospho- nate residronate reduces metastatic human breast cancer burden in nude mice.Cancer Res 55: 3551\u20133557, 1995.","journal-title":"Cancer Res"},{"key":"BF02967623_CR13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","volume":"99","author":"T Yoneda","year":"1997","unstructured":"Yoneda T, Sasaki A, Dunstan C,et al: Inhibition of osteolytic bone metastases of breast cancer by combined treatment with bisphosphonate and tissue inhibitor of matrix metalloproteinase-2.J Clin Invest 99: 2509\u20132517, 1997.","journal-title":"J Clin Invest"},{"key":"BF02967623_CR14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN,et al: Pamidronate reduces skeletal morbidity in woman with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.J Clin Oncol 17: 846\u2013854, 1999.","journal-title":"J Clin Oncol"},{"key":"BF02967623_CR15","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A,et al: Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.J Clin Oncol 16: 2038\u20132044, 1998.","journal-title":"J Clin Oncol"},{"key":"BF02967623_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","volume":"10","author":"RE Coleman","year":"1999","unstructured":"Coleman RE, Purohit OP, Black C,et al: Double-blind, randomized, placebo control, dose-finding study of oral ibandronate in patients with metastatic bone disease.Ann Oncl 10: 311\u2013316, 1999.","journal-title":"Ann Oncl"},{"key":"BF02967623_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","volume":"3","author":"AH Paterson","year":"1950","unstructured":"Paterson AH, Powles TJ, Kanis JA,et al: Double-blind controlled trial of oral analysis of 1000 autopsied cases.Cancer 3: 74\u201376, 1950.","journal-title":"Cancer"},{"key":"BF02967623_CR18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Bastert G,et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment.N Engl J Med 339: 357\u2013363, 1998.","journal-title":"N Engl J Med"},{"issue":"(suppl 11)","key":"BF02967623_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/sonc.2001.25429","volume":"28","author":"IJ Diel","year":"2001","unstructured":"Diel IJ: Bisphosphonates in prevention of bone metastases: current evidence.Semin Oncol 28(suppl 11): 75\u201380, 2001.","journal-title":"Semin Oncol"},{"key":"BF02967623_CR20","first-page":"468","volume":"17","author":"TJ Powel","year":"1998","unstructured":"Powel TJ, Paterson AHG, Nevantus A,et al: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer.Proc Am Soc Clin Oncol 17: 468, 1998.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF02967623_CR21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","volume":"19","author":"T Saarto","year":"2001","unstructured":"Saarto T, Blomqvist C, Virkkunen P,et al: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized control trial.J Clin Oncol 19: 10\u201317, 2001.","journal-title":"J Clin Oncol"},{"key":"BF02967623_CR22","unstructured":"Kokufu I, Kohno N: Adjuvant pamidronate treatment reduces the incidence of bone metastases in patients with over 4 positive nodes, (submitted)"},{"issue":"(suppl ll)","key":"BF02967623_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/sonc.2001.25440","volume":"28","author":"AHG Paterson","year":"2001","unstructured":"Paterson AHG: Adjuvant bisphosphonate therapy: the future.Semin Oncol 28(suppl ll): 81\u201385, 2001.","journal-title":"Semin Oncol"},{"key":"BF02967623_CR24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hiller","year":"2000","unstructured":"Hiller BE, Ingle JN, Berenson JR: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.J Clin Oncol 18: 1378\u20131391, 2000.","journal-title":"J Clin Oncol"},{"key":"BF02967623_CR25","unstructured":"Smith R, Jipling W, Bryant J,et al: Primary breast cancer as risk factor for bone recurrence: NSABP Experience.Proc Am Soc Clin Oncol 18: 1999."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02967623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02967623\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02967623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T21:11:26Z","timestamp":1558473086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02967623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["BF02967623"],"URL":"https:\/\/doi.org\/10.1007\/bf02967623","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}